Division of Hematology, The Ohio State University, 320 West 10th Avenue, A340 Starling Loving Hall, Columbus, OH 43210, USA.
Division of Hematology, The Ohio State University, 320 West 10th Street, A350C Starling Loving Hall, Columbus, OH 43210, USA. Electronic address: https://twitter.com/kmaddmd.
Hematol Oncol Clin North Am. 2020 Oct;34(5):903-921. doi: 10.1016/j.hoc.2020.06.007. Epub 2020 Aug 1.
The Bruton tyrosine kinase inhibitors (BTKi), acalabrutinib, ibrutinib, and zanubrutinib, are all approved in the United States for the treatment of relapsed mantle cell lymphoma (MCL). BTKi as a class have become the preferred therapy for most of the patients with relapsed MCL, and ongoing clinical trials are evaluating whether combining BTKi with other targeted agents may deepen response and further improve outcomes. Emerging evidence supports the efficacy of BTKi-containing combinations as frontline treatment, and clinical studies to define the role of this class of drugs for newly diagnosed patients with MCL are in progress.
布鲁顿酪氨酸激酶抑制剂（BTKi），阿卡替尼、伊布替尼和泽布替尼，均已获美国批准用于治疗复发套细胞淋巴瘤（MCL）。BTKi 类药物已成为大多数复发 MCL 患者的首选治疗方法，正在进行的临床试验正在评估 BTKi 与其他靶向药物联合应用是否可以加深缓解并进一步改善结果。新出现的证据支持 BTKi 联合治疗的疗效作为一线治疗，正在进行的临床研究旨在确定该类药物在新诊断的 MCL 患者中的作用。
